

# **Janssen-Cilag:**

## **Description for PharmaForum 2009**

### **1. Company**

Janssen-Cilag, an affiliate of global health-care leader Johnson & Johnson, is an internationally operating, research-based pharmaceutical manufacturer. A staff of 1,000 employees working in the fields of pharmaceuticals and biotechnology as well as a turnover of 481 million Euros place our company among the leading pharmaceutical manufacturers in the German market. Managing Director of Janssen-Cilag Germany is Kris Sterkens.

Our products and services drive the progress in medical care and improve the quality of life of both patients and their relatives. Research and development of new drugs is the top priority within our global group of companies.

### **2. Core Competences**

Janssen-Cilag discovers, develops, manufactures and markets innovative drugs and therapies to help patients to improve their quality of life. Many of our pharmaceutical products have received major awards. Five substances from among more than 80 drugs which our research has developed are listed on the World Health Organization's Essential Medicines List:

- Ethinylestradiol + Norethisteron
- Haloperidol
- Levamisol
- Mebendazol
- Miconazol

## **Key therapeutic areas and products**

Pain/Internal Medicine: Durogesic<sup>®</sup> SMAT, Journista<sup>®</sup> und Topamax<sup>®</sup> Migräne

Asthma: Inuvair<sup>®</sup>

Geriatrics: Reminyl<sup>®</sup>

Psychiatrie: Risperdal<sup>®</sup>, Risperdal<sup>®</sup> Consta<sup>®</sup> and Invega<sup>®</sup>

Neurology: Concerta<sup>®</sup> und Topamax<sup>®</sup>

Oncology: Velcade<sup>®</sup>

Virology/Infectiology: Prezista<sup>®</sup>, Intelence<sup>®</sup>

Urology: Priligy

## **Biotechnology**

Anaemia (Oncology, Nephrology): Erypo<sup>®</sup>

Psoriasis: Stelara<sup>®</sup>

## **3. Cooperations offered and requested**

Janssen-Cilag constantly seeks:

- Novel therapeutic agents and drug targets in our key therapeutic areas
- Innovative solutions to improve the individual therapy for patients

Search fields of Janssen-Cilag: Focus on unmet medical needs and innovative solutions

## **4. Short CV of Speaker**

Prof. Dr. med. Günter Huhle is Member of the Management Board Janssen-Cilag and Head of Medical and Scientific Affairs. In this function he is responsible for Pharmacovigilance, Regulatory Affairs, Clinical trial execution, Medical information and Medical education including strategic planning, budget and resource allocation.

Günter Huhle received his MD and PhD from the University of Heidelberg and his Master of Science in Pharmaceutical Medicine from the University of Witten/Herdecke. He specialized in Internal Medicine and Haemostaseology and has been appointed University Lecturer for Internal Medicine at the

University of Heidelberg. Since 2001, Günter Huhle has held national and international senior Management positions in the pharmaceutical Industry until joining the Management board of Janssen Cilag in 2008. He is married and has two sons.